ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO534

Recurrent FSGS in Renal Transplantation: A Single Centre Experience

Session Information

Category: Glomerular

  • 1005 Clinical Glomerular Disorders


  • Antonelou, Marilina, University College London, Centre For Nephrology, London, United Kingdom
  • sadeghi-alavijeh, Omid, University College London, Centre For Nephrology, London, United Kingdom
  • Gale, Daniel P., University College London, Centre For Nephrology, London, United Kingdom
  • Jones, Gareth L, Royal Free London NHS Trust, London, United Kingdom
  • Salama, Alan D., University College London, Centre For Nephrology, London, United Kingdom

Renal transplantation in patients with Focal segmental glomerulosclerosis (FSGS) is often complicated by disease recurrence which is associated with poor outcome. There are no reliable tests to predict recurrence of FSGS after transplantation. The aim of this study was to evaluate if clinical criteria can identify patients at high risk for recurrent disease.


Retrospective review of patients diagnosed with FSGS who received a renal transplant in our centre between 1995 and 2017. The diagnosis of primary FSGS was based on a native renal biopsy or unexplained proteinuria and a family history of kidney disease. Recurrence of FSGS was defined as the occurrence of proteinuria, greater than 100 mg/mmol after transplantation with histological evidence of FSGS.


We identified 99 patients with FSGS who received a kidney transplant. Twenty five (25.2%) had biopsy proven recurrent FSGS. The median interval from transplantation to onset of proteinuria was 3.1(1-28)months. A comparison of baseline and follow-up data is shown in Table 1. The median interval between onset of proteinuria and a renal biopsy confirming the diagnosis of recurrent FSGS was 2.7(1.1-4.3) months. Nine patients did not have histological evidence of FSGS on their initial biopsy. None of the 25 patients with recurrent FSGS had a family history of kidney disease. Seven patients had a previous failed transplant, four following FSGS recurrence.


Our data suggest that primary, as opposed to secondary FSGS is a reliable marker of increased recurrence risk in patients with FSGS undergoing renal transplantation. The family history is a useful tool for risk stratification. Close monitoring for proteinuria is important for the initiation of treatment as histological changes might not be present at the early disease stage.

 Recurrence (n=25)No recurrence (n=74)p value
Gender (male,%)14(56)45(60.8)0.81
Age of onset of disease (years)26(16-43)37(30-47)0.14
Primary FSGS (n,%)24(96)57(77)0.03
Family history of kidney disease (n,%)09(12.2)0.10
Live donor (n,%)
Cadaveric donor (n,%)
Patients with ≥1 failed transplant (n,%)7(28)5(6.8)0.001
Interval from transplantation to last follow-up (LTFU) (years)2.9(1.5-15.4)8.1(3.1-15.3)0.09
Creatinine at LTFU (mmol/L)167(123-347)139(108-188)0.19
RRT dependent at LTFU (n,%)10(40)6(8.1)<0.001
Death (n,%)5(20)8(10.8)0.30